- Home
- SWIM vs RLMD Comparison
SWIM vs RLMD Comparison
Compare SWIM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWIM | RLMD |
|---|---|---|
| Founded | 1956 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.5M | 661.9M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SWIM | RLMD |
|---|---|---|
| Price | $6.14 | $6.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.75 | ★ $12.40 |
| AVG Volume (30 Days) | 881.5K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.00 | 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $545,912,000.00 | $13,070.00 |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.35 | ★ 154.83 |
| 52 Week Low | $4.64 | $0.55 |
| 52 Week High | $8.97 | $8.00 |
Technical Indicators
Market Signals| Indicator | SWIM | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 42.80 |
| Support Level | $5.07 | $6.17 |
| Resistance Level | $6.81 | $7.34 |
| Average True Range (ATR) | 0.27 | 0.45 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 56.49 | 1.75 |
Price Performance
Historical ComparisonAbout SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.